Arvinas, Inc. (NASDAQ:ARVN) Receives $59.73 Consensus PT from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been given a consensus recommendation of “Moderate Buy” by the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $59.73.

Several brokerages have weighed in on ARVN. Wedbush boosted their price target on Arvinas from $33.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. BMO Capital Markets boosted their price target on Arvinas from $89.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. HC Wainwright cut their price target on Arvinas from $90.00 to $87.00 and set a “buy” rating for the company in a report on Friday, April 12th. The Goldman Sachs Group started coverage on Arvinas in a report on Thursday, February 1st. They set a “buy” rating and a $70.00 price objective for the company. Finally, Truist Financial restated a “buy” rating and set a $65.00 price objective on shares of Arvinas in a report on Monday, March 25th.

Arvinas Price Performance

Shares of Arvinas stock opened at $34.00 on Friday. Arvinas has a 1 year low of $13.57 and a 1 year high of $53.08. The company has a market capitalization of $2.32 billion, a P/E ratio of -5.23 and a beta of 1.94. The business has a 50 day moving average price of $42.95 and a 200 day moving average price of $34.39.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($1.38). The business had revenue of ($43.10) million during the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. During the same quarter last year, the firm posted ($1.56) earnings per share. As a group, research analysts expect that Arvinas will post -5.02 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

In other Arvinas news, insider Ronald Peck sold 1,699 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the completion of the transaction, the insider now directly owns 67,516 shares of the company’s stock, valued at approximately $3,176,627.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Arvinas news, insider Ronald Peck sold 1,699 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the completion of the transaction, the insider now directly owns 67,516 shares of the company’s stock, valued at approximately $3,176,627.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares of the company’s stock, valued at $8,559,147.80. The disclosure for this sale can be found here. Insiders sold a total of 8,597 shares of company stock valued at $404,489 in the last ninety days. Insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cullinan Associates Inc. acquired a new stake in shares of Arvinas in the 1st quarter valued at about $248,000. Allspring Global Investments Holdings LLC raised its stake in shares of Arvinas by 9.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 12,570 shares of the company’s stock valued at $519,000 after purchasing an additional 1,060 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Arvinas by 71.4% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 61,862 shares of the company’s stock valued at $2,554,000 after purchasing an additional 25,778 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Arvinas by 7.1% in the 1st quarter. Los Angeles Capital Management LLC now owns 29,882 shares of the company’s stock valued at $1,234,000 after purchasing an additional 1,993 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Arvinas in the 4th quarter valued at about $3,046,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.